Rafferty Asset Management LLC Sells 84,802 Shares of Dynavax Technologies Corporation $DVAX

Key Points

• Rafferty Asset Management LLC has reduced its stake in Dynavax Technologies by 34%, now owning approximately 0.14% of the company, equivalent to $2.13 million.
• Director Scott Dunseth Myers purchased 3,800 shares of Dynavax, increasing his holdings by 12.18% and bringing his total to 35,004 shares valued at over $378,000.
• Dynavax Technologies recently reported an EPS of $0.14 for the last quarter, surpassing estimates, and has a current consensus rating of "Moderate Buy" with a price target of $24.33.

Rafferty Asset Management LLC reduced its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 34.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 164,371 shares of the biopharmaceutical company's stock after selling 84,802 shares during the period. Rafferty Asset Management LLC owned 0.14% of Dynavax Technologies worth $2,132,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in DVAX. Walleye Capital LLC boosted its holdings in Dynavax Technologies by 50,734.1% during the first quarter. Walleye Capital LLC now owns 266,879 shares of the biopharmaceutical company's stock worth $3,461,000 after buying an additional 266,354 shares during the last quarter. AlphaQuest LLC raised its position in shares of Dynavax Technologies by 134.3% in the 1st quarter. AlphaQuest LLC now owns 54,920 shares of the biopharmaceutical company's stock valued at $712,000 after acquiring an additional 31,483 shares during the period. Advantage Alpha Capital Partners LP boosted its stake in Dynavax Technologies by 53.2% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 38,443 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 13,345 shares during the last quarter. American Century Companies Inc. grew its holdings in Dynavax Technologies by 11.5% during the first quarter. American Century Companies Inc. now owns 291,883 shares of the biopharmaceutical company's stock valued at $3,786,000 after purchasing an additional 30,081 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,304 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Dynavax Technologies

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the acquisition, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.98% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JMP Securities reissued a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Stock Down 2.1%

NASDAQ:DVAX traded down $0.22 on Thursday, hitting $9.92. 802,109 shares of the company's stock were exchanged, compared to its average volume of 2,078,266. The firm has a 50-day moving average price of $10.63 and a 200-day moving average price of $11.26. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. The company has a market cap of $1.16 billion, a P/E ratio of -21.55 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.